Human and Mouse Microglia React Differently to Amyloid
Single-nucleus transcriptomics of postmortem AD brain and mouse models of amyloidosis hammers home the species-specific responses of microglia to Aβ pathology.
ALL NEWS
206 RESULTS
Sort By:
Tau PET Scans Turn Positive When Amyloid Does; Symptoms Follow
Data from different next-generation tracers look similar. It shows spreading plaques kick off tangles by Braak region; memory starts slipping later.
2019—A Year of Hope for Alzheimer's Research
Happy New Year, readers! Yes, 2019 has passed, but so much happened last year that capturing the essence took longer than usual. Our mega year-end story is now posted for your reading pleasure.
Exposure, Exposure, Exposure? At CTAD, Aducanumab Scientists Make a Case
Biogen researchers claim the antibody worked in people who got enough of it. To other researchers, the signal validates the amyloid hypothesis and injects fresh energy into the field. But is this interrupted dataset enough to approve?
Multimodal Imaging of Neurodegenerative Diseases Links Pathology and Cellular Dysfunction
Synapse loss and mitochondrial stress, as seen by separate PET tracers, go hand-in-hand in Alzheimer’s, Parkinson’s, and frontotemporal dementia.
Paper Alert: Phase 3 Trial Data Published on Sleep Aid Suvorexant
FDA approves adding safety and efficacy data from an Alzheimer’s trial to the drug’s label.
New Myelin Makes Memories, but Supply Wanes with Age
The creation of long-term memories requires a continual supply of myelin provided by newly formed oligodendrocytes. Alas, the generation of fresh oligodendrocytes diminishes with age, along with memory.
Toxic α-Synuclein: Egged on by ApoE4, Thwarted by ApoE2?
Quite independently of what it does to Aβ or tau, ApoE4 stokes α-synuclein pathology in mouse models. People with Lewy body dementia who carry ApoE4 had more phosphorylated synuclein in their brains, and their cognition declined faster.
Topline Result for First DIAN-TU Clinical Trial: Negative on Primary
DIAN, Roche, Lilly disclose that neither gantenerumab nor solanezumab slowed cognitive decline in the first-pass comparison of drug and placebo groups. Analyses are ongoing; dose may have been too low.
A Central Role for Prion Protein in Neurodegeneration?
Researchers implicate PrP in the toxicity of Aβ, tau, and α-synuclein oligomers in several neurodegenerative diseases.
Retinal Gene Therapy Trial Posts Positive Result
Vision improved in some retinitis pigmentosa patients in a Phase 1 trial.
PET Tracer Detects Synapse Loss Across Alzheimer’s Brain
New research presented at the HAI conference also finds links between UCB-J uptake and plaques, tangles, and cognitive decline.
Can PET Match Up Areas of Protein Deposit With Alzheimer’s Symptoms?
Amyloid and tau PET are helping scientists pinpoint the underlying cause of specific AD symptoms. Perhaps imaging of certain brain regions will help predict an individual’s progression.
How Much Amyloid Will Kick Off Tangles, and Decline?
At HAI 2020, scientists more precisely quantified the relationship between plaques, tangles, and cognitive decline.
Is Too Much Vitamin B12 a Health Hazard?
When observed over an eight-year period, people with the highest plasma concentrations were more likely to die than people with lower levels.
Current Filters
- Date Range : Nov 2019 to Nov 2020 x